(Source: Roche Holding AG) Basel, 3 November 2015 Roche expands cobas 4800 System menu with HIV-1, HCV and HCV Genotyping Tests System portfolio broadens to include high medical value virology assays Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial availability of the cobas HIV-1, HCV and HCV Genotyping (GT) assays in countries accepting the CE mark1. These new molecular diagnostic assays increase the available menu on the cobas 4800 System, further improving efficiency and flexibility that allows laboratories to deliver results for rapid clinical decisions. The new virology assays offer the latest generation of performance with dual target technology for HIV-1 and dual...
↧